Neoadjuvant Iparomlimab and Tuvonralimab With Nab-P-SOX in Locally Advanced Gastric or Gastroesophageal Junction Cancer
NCT07867392
Summary
This is a single-center, single-arm, phase 2 clinical study testing a new neoadjuvant (pre-surgery) treatment for patients with locally advanced gastric cancer or gastroesophageal junction (GEJ) cancer. The treatment combines two parts: (1) a novel bispecific immunotherapy drug, iparomlimab and tuvonralimab (Qibain®) , which helps the immune system attack cancer cells by blocking the PD-1 and CTLA-4 pathways; and (2) a standard chemotherapy regimen called nab-P-SOX, made up of nab-paclitaxel, oxaliplatin, and S-1. About 28 adults (aged 18-75) with previously untreated, HER2-negative, locally advanced gastric or GEJ adenocarcinoma (clinical stage cT3-4aN+M0) will receive this combination before their planned surgery. The main goal is to see how well the tumor shrinks, measured by the objective response rate (RECIST v1.1). Secondary goals include the rate of complete response in the removed tumor tissue (pathological complete response), how often the cancer is removed with clear margins (R0 resection), survival outcomes, and the safety of the treatment. All participants will be closely followed to track both benefits and side effects. The study is sponsored by Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, with funding and the study drug provided by Qilu Pharmaceutical Co., Ltd.
Eligibility
Inclusion Criteria: * Age 18-75 years * Histologically confirmed gastric or gastroesophageal junction adenocarcinoma, clinical stage cT3-4aN+M0 * Resectable disease, as determined by the surgical investigator * No prior radiotherapy, chemotherapy, or other systemic antitumor therapy * HER-2 negative * ECOG performance status 0-1 * Life expectancy greater than 6 months * Adequate organ function: hemoglobin \>= 90 g/L; absolute neutrophil count \>= 1.5 x 10\^9/L; platelet count \>= 100 x 10\^9/L; serum creatinine \<= 1.5 x ULN; ALT/AST \<= 2.5 x ULN; total bilirubin \<= 1.5 x ULN; amylase/lipase \< 1.5 x ULN; INR/APTT \<= 1.5 x ULN; urine protein \< 2+; LVEF \>= 50% * Women of childbearing potential must be non-pregnant, non-lactating, and agree to use adequate contraception * Provision of written informed consent and anticipated good compliance Exclusion Criteria: * Known allergy or hypersensitivity to the investigational drug(s) or excipients * History of other prior antitumor therapy * Therapeutic full-dose anticoagulation or thrombolysis within 10 days prior to first dose * Requirement for systemic corticosteroids or immunosuppressive therapy within 2 weeks prior to first dose * Active autoimmune disease or autoimmune disease with high risk of relapse * Within 6 months: gastrointestinal perforation, fistula, or obstruction; Crohn's disease or ulcerative colitis; or extensive intestinal resection * Symptomatic and uncontrolled brain or leptomeningeal metastases * History of interstitial lung disease/pneumonitis or pulmonary hypertension * History of organ transplantation * Uncontrolled hypertension (\>150/100 mmHg), diabetes mellitus, or cardiac arrhythmia * Arterial or venous thrombotic/embolic event within 6 months * Within 12 months: myocardial infarction, unstable angina, or NYHA class III/IV heart failure * Drainage of ascites, pleural effusion, or pericardial effusion within 4 weeks prior to enrollment * Non-healing wound, active ulcer, or untreated fracture * Other active malignancy * Active HIV, HBV, or HCV infection * Major surgery within 4 weeks prior to first dose * Any condition that, in the investigator's judgment renders the patient unsuitable for study participation
Conditions2
Interventions2
Related trials
- Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer — Beijing Friendship Hospital
- Iparomlimab and Tuvonralimab Plus Paclitaxel and Platinum as Neoadjuvant Therapy for Locally Advanced Cervical Cancer — Sun Yat-sen University
- Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus — Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence — Tongji Hospital
- QL1706(Iparomlimab/Tuvonralimab) Combined With Gemcitabine and Cisplatin as First-Line Treatment for PD-L1-Positive Biliary Tract Cancer — Shanghai Zhongshan Hospital
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT07867392